Esomeprazole vs. Omeprazole for Patients with GERD
DA Johnson
Abstract
DA Johnson
Abstract
Proton-pump inhibitors (PPIs) form the recognized cornerstone of therapy for gastroesophageal reflux disease (GERD). Sustained maintenance of pH higher than 4 has correlated with prompt resolution of GERD symptoms and high rates of esophagitis healing. To date, none of the newer PPIs -- lansoprazole, rabeprazole, or pantoprazole -- have proven significantly better than omeprazole at maintaining pH higher than 4, when clinically relevant endpoints were used. Compared with omeprazole, its S-isomer (esomeprazole) …
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Proton-pump inhibitors (PPIs) form the recognized cornerstone of therapy for gastroesophageal reflux disease (GERD). Sustained maintenance of pH higher than 4 has correlated with prompt resolution of GERD symptoms and high rates of esophagitis healing. To date, none of the newer PPIs -- lansoprazole, rabeprazole, or pantoprazole -- have proven significantly better than omeprazole at maintaining pH higher than 4, when clinically relevant endpoints were used. Compared with omeprazole, its S-isomer (esomeprazole) …
Key concepts: Esomeprazole, GERD, Omeprazole, Lansoprazole, Medicine, Rabeprazole, Pantoprazole, Gastroenterology